BidaskClub Upgrades Theravance Biopharma (TBPH) to “Strong-Buy”

BidaskClub upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a buy rating to a strong-buy rating in a report issued on Thursday morning.

Other equities analysts have also issued reports about the stock. ValuEngine raised shares of Theravance Biopharma from a hold rating to a buy rating in a report on Friday, November 30th. Piper Jaffray Companies reaffirmed a buy rating on shares of Theravance Biopharma in a report on Tuesday, October 23rd. Cantor Fitzgerald reaffirmed a buy rating and issued a $55.00 price target on shares of Theravance Biopharma in a report on Monday, October 22nd. Leerink Swann set a $38.00 price target on shares of Theravance Biopharma and gave the stock a buy rating in a report on Wednesday, November 7th. Finally, Zacks Investment Research reaffirmed a strong-buy rating and issued a $29.00 price target on shares of Theravance Biopharma in a report on Friday, November 16th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $43.40.

NASDAQ TBPH traded up $0.10 on Thursday, hitting $27.15. The stock had a trading volume of 108,300 shares, compared to its average volume of 165,137. The company has a current ratio of 3.26, a quick ratio of 3.08 and a debt-to-equity ratio of 6.52. Theravance Biopharma has a 52-week low of $21.27 and a 52-week high of $35.48. The firm has a market capitalization of $1.51 billion, a P/E ratio of -4.98 and a beta of 1.89.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.18) by $0.08. Theravance Biopharma had a negative net margin of 513.41% and a negative return on equity of 505.90%. The business had revenue of $12.84 million for the quarter, compared to analyst estimates of $10.55 million. As a group, sell-side analysts predict that Theravance Biopharma will post -4.18 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc lifted its stake in shares of Theravance Biopharma by 3.6% during the third quarter. Vanguard Group Inc now owns 3,672,030 shares of the biopharmaceutical company’s stock worth $119,965,000 after buying an additional 126,135 shares during the period. Vanguard Group Inc. lifted its stake in shares of Theravance Biopharma by 3.6% during the third quarter. Vanguard Group Inc. now owns 3,672,030 shares of the biopharmaceutical company’s stock worth $119,965,000 after buying an additional 126,135 shares during the period. TIAA CREF Investment Management LLC lifted its stake in shares of Theravance Biopharma by 27.7% during the third quarter. TIAA CREF Investment Management LLC now owns 158,966 shares of the biopharmaceutical company’s stock worth $5,193,000 after buying an additional 34,495 shares during the period. Teachers Advisors LLC lifted its stake in shares of Theravance Biopharma by 29.1% during the third quarter. Teachers Advisors LLC now owns 139,815 shares of the biopharmaceutical company’s stock worth $4,568,000 after buying an additional 31,552 shares during the period. Finally, Man Group plc acquired a new stake in shares of Theravance Biopharma during the third quarter worth $292,000. Institutional investors and hedge funds own 83.93% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.

Featured Article: Treasury Bonds

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply